Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Shares (Common, Diluted) 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 12.24%

Monte Rosa Therapeutics Inc Shares (Common, Diluted) 3 year CAGR is 12.24% for the Trailing 12 Months (TTM) ending March 31, 2024, a -61.04% change year over year. Shares (Common, Diluted) represent the number of common shares outstanding, including potential dilution from stock options, convertible securities, or other instruments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Monte Rosa Therapeutics Inc Shares (Common, Diluted) for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 49.35 M, a 5.91% change year over year.
Monte Rosa Therapeutics Inc Shares (Common, Diluted) for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 46.60 M, a 9.53% change year over year.
Monte Rosa Therapeutics Inc Shares (Common, Diluted) for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 42.54 M, a 95.70% change year over year.
Monte Rosa Therapeutics Inc Shares (Common, Diluted) for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 21.74 M.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends